Table 1.

Breast cancer in MtF transgender patients receiving estrogen, in the literature

Study	Tumour type	Age	Duration of estrogen therapy	Receptor status
Symmers2	Primary mammary adenocarcinoma	30	5 years	NA
Symmers2	Intraductal adenocarcinoma	30	Unknown	NA
Pritchard et al3	Invasive ductal carcinoma	35	10 years	ER−, PR +
Ganly and Taylor4	Invasive ductal carcinoma	36	14 years	ER−, PR NA
Grabellus et al5	Secretory breast carcinoma, ETV6-NTRK3 gene fusion	46	8 years	ER−, PR−, HER2−
Kelley6	Phyllodes*	53	Unknown but ≥8 years	ER−, PR−, HER2−
Dhand and Dhaliwal 7	Needle aspiration	58	11 years	ER+, PR+, HER2 NA
Pattison and McLaren8	Invasive ductal carcinoma	43	13 years	ER−, PR−, HER2−
Gooren et al9	Ductal carcinoma	57	36 years	ER+, PR−, HER2−
Gooren et al9	Poor differentiated carcinoma in lymph nodes†	56	Unknown but ≥8 years	NA
Maglione et al10	Ductal carcinoma in situ*	65	13 years	ER+, PR+, HER2 NA
Maglione et al10	Invasive ductal carcinoma	55	30 years	ER−, PR−, HER2+
Sattari11	Infiltrating ductal carcinoma	60	8 years	ER+, PR+, HER2−
Gooren et al12	Invasive ductal carcinoma*	46	Unknown but ≥6 years	ER+, PR+, HER2+
Gooren et al12	Adenocarcinoma	52	30 years	ER+, PR−, HER2 NA
Teoh et al	Invasive ductal carcinoma	41	14 years	ER−, PR−, HER2−

*Family history of breast cancer.

†Primary origin most likely from breast tumour removed 10 years earlier but not proven histologically.

ER, estrogen receptor; ETV6, ETS variant gene; HER2, human epidermal growth factor receptor 2; MtF, male-to-female; NA, not applicable; NTRK3, neurotrophic tyrosine kinase receptor type 3; PR, progesterone receptor.